UMB Bank n.a. Decreases Position in Pfizer Inc. (NYSE:PFE)

UMB Bank n.a. lessened its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 581,700 shares of the biopharmaceutical company’s stock after selling 33,490 shares during the quarter. UMB Bank n.a.’s holdings in Pfizer were worth $29,807,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in PFE. Karp Capital Management Corp purchased a new position in Pfizer in the 3rd quarter worth $27,000. Worth Asset Management LLC purchased a new position in shares of Pfizer in the first quarter valued at about $29,000. Delos Wealth Advisors LLC increased its position in shares of Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 400 shares during the period. Legend Financial Advisors Inc. purchased a new position in shares of Pfizer in the third quarter valued at about $42,000. Finally, Align Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Trading Down 0.7 %

NYSE:PFE opened at $40.10 on Friday. Pfizer Inc. has a one year low of $39.23 and a one year high of $56.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. The company’s 50-day simple moving average is $43.26 and its 200 day simple moving average is $46.03. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. During the same quarter in the prior year, the firm posted $1.08 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Barclays decreased their price objective on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 1st. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a research report on Monday, February 27th. SVB Leerink decreased their price objective on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective on the stock in a research report on Tuesday, February 7th. Finally, Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $50.38.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.